论文部分内容阅读
卡铂为主联合化疗治疗恶性肿瘤471例。卡铂剂量160～422mg/m~2,静滴,分一次、二次或五次给药。对小细胞肺癌、卵巢癌、睾丸肿瘤及恶性淋巴瘤疗效显著,有效率分别为59.5％、92.3％、60.0％和87.5％。对头颈部肿瘤、食管癌、乳腺癌、非小细胞肺癌及原发灶不明的转移癌也有效。CE方案对食管癌效果较好,其它卡铂联合方案对肺腺癌较好,两组方案治疗小细胞肺癌、肺鳞癌、恶性淋巴瘤和头颈部肿瘤疗效相近。另有158例随诊毒性转归,多在短期内恢复,未发现严重反应。
Carboplatin-based combination chemotherapy was used to treat 471 cases of malignant tumors. Carboplatin dose 160 ~ 422mg/m ~ 2, intravenous infusion, once, twice or five doses. The efficacy of small cell lung cancer, ovarian cancer, testicular tumors, and malignant lymphomas was significant. The effective rates were 59.5%, 92.3%, 60.0%, and 87.5%, respectively. It is also effective for head and neck cancer, esophageal cancer, breast cancer, non-small cell lung cancer and metastases with unknown primary tumors. The CE regimen has a good effect on esophageal cancer. Other carboplatin combination regimens are better for lung adenocarcinoma. The two groups have similar efficacy in the treatment of small cell lung cancer, lung squamous cell carcinoma, malignant lymphoma and head and neck cancer. Another 158 patients were followed up for toxicity and recovered in the short term. No serious reactions were found.